Pharmacological inhibition of tissue factor

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 1, 2006, Pages 71-76

  Laterre, Pierre Francois ^a   Wittebole, Xavier ^a   Collienne, Christine ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Animal models; DIC; Sepsis; SIRS; Tissue factor; Tissue factor pathway inhibitor (TFPI)

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; FIBRIN DEGRADATION PRODUCT; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 6; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; CANCER GROWTH; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRIN DEPOSITION; HUMAN; INFLAMMATION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 33644555817     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-933342     Document Type: Review

References (29)

1. Lupu C, Westmuckett AD, Peer G, et al. Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis. Am J Pathol 2005;167:1161-1172
2. Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001;86:66-74
3. Marmur JD, Thiruvikraman SV, Fyfe BS, et al. Identification of active tissue factor in human atherosclerotic plaques in human coronary atheroma. Circulation 1996;94:1226-1232
4. Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992;70:1194-1201
5. Ryan J, Brett J, Tijburg P, et al. Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface. Blood 1992;80:966-974
6. Rivers RP, Hathaway WE, Weston WL. The endotoxin-induced coagulant activity of human monocytes. Br J Haematol 1975;30:311-316
7. van der Poll T, de Jonge E, Levi M, et al. Pathogenesis of DIC in sepsis. Sepsis 1999;3:103-109
8. Levi M, de Jonge E, van der Poll T, et al. Disseminated intravascular coagulation. Thromb Haemost 1999;82:695-705
9. Sevinsky JR, Rao LV, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996;133:293-304
10. Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997;78:471-477
11. Gando S, Kameue T, Matsuda N, et al. Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients. Thromb Res 2003;109:119-124
12. Gando S, Kameue T, Morimoto Y, et al. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002;30:1729-1734
13. Park CT, Creasey AA, Wright S. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood 1997;89:4268-4274
14. Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA 2001;98:7742-7747
15. Warr TA, Rao LV, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: Effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990;75:1481-1489
16. Levi M, ten Cate H, Bauer KA, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994;93:114-120
17. Taylor FB Jr, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991;33:127-134
18. Creasey AA, Chang ACK, Feigen L, et al. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91:2850-2860
19. Carr C, Bild GS, Chang AC, et al. Recombinant E coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 1994;44:126-137
20. Enkhbaatar P, Okajima K, Murakami K, et al. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. Am J Respir Crit Care Med 2000;162:1752-1759
21. Opal S, Palardy JE, Parejo NA, Creasey AA. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intraabdominal sepsis. Crit Care Med 2001;29:13-17
22. Welty-Wolf KE, Carraway MS, Miller DL, et al. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 2001;164:1988-1996
23. Miller DL, Welty-Wolf K, Carraway MS, et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 2002;26:650-658
24. de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000;95:1124-1129
25. de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis 2001;183:1815-1818
26. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomised, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001;29:2081-2089
27. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of Tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis. JAMA 2003;290:238-247
28. Enjyoji K, Miyata T, Kamikubo Y, Kato H. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. Biochemistry 1995;34:5725-5735
29. Opal S, Wunderink R, Laterre PF, et al. Therapeutic rationale for tissue factor pathway inhibitor for severe community-acquired pneumonia (CAP (abstract 234). In: Final program and abstracts of 42nd Annual Meeting Infections Disease Society of America; September 30-October 3, 2004; Boston, MA